Rezolute
Louisville
About Rezolute
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio including RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $494.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2025)
- Ticker: nasdaq:RZLT
- Website: rezolutebio.com
- Phone: (303) 222-2128
Industries & Categories
Biotechnology, Diabetes, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rezolute-58437 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.